Loading…
Loading…
As of 20 Nov 2026: ACUTAAS ₹3,833.50 (m-cap ₹31,396 Cr, P/E 71.5) vs ONESOURCE ₹1,609.30 (m-cap ₹18,507 Cr). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | ACUTAAS | ONESOURCE |
|---|---|---|
| Share price | ₹3,833.50 | ₹1,609.30 |
| Day change | −3.61% | +0.40% |
| Market cap | ₹31,396 Cr | ₹18,507 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 71.5 | — |
| P/BPrice ÷ book value per share. | 16.9 | 3.1 |
| ROEReturn on equity. | 24.0% | -1.1% |
| ROCEReturn on capital employed. | 32.0% | 1.0% |
| Sales growth (3Y CAGR) | 29.5% | 232.0% |
| Profit growth (3Y CAGR) | 62.0% | 23.9% |
| Debt to equity | 0.02 | 0.26 |
| Dividend yield | 0.07% | 0.00% |
| 1-year price return | +121.3% | −3.8% |
| Promoter holding | 32.7% | 30.5% |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Acutaas Chemicals Ltd is larger, with a market cap of ₹31,396 Cr against ₹18,507 Cr for OneSource Specialty Pharma Ltd as of 20 Nov 2026 — about 1.7 times the size.
OneSource Specialty Pharma Ltd has no meaningful P/E right now (a loss over the last twelve months, or no reported earnings), so the two cannot be compared on P/E.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.